Shots:
- Neurocrine Biosciences has initiated a P-II study of investigational NBI-1065890 in adults with TD
- P-II study of NBI-1065890 will enroll ~100 adults with TD, evaluating efficacy, safety, and tolerability, with the 1EP being change from baseline in Abnormal Involuntary Movement Scale (AIMS) total score at Wk 8
- NBI-1065890 is a selective oral VMAT2 inhibitor in clinical development for tardive dyskinesia
Ref: Neurocrine Biosciences | Image: Neurocrine Biosciences | Press Release
Related News: TransThera Sciences Inks Up to $881.5M Deal with Neurocrine Biosciences to Advance NLRP3 Inhibitors
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
